TrialCancer2025

A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Chong-Sheng Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.